Projects per year
Personal profile
Personal profile
Dr. Biana Godin earned her Ph.D. in Pharmaceutical Sciences from the Hebrew University of Jerusalem in 2006. During her Ph.D. studies, Dr. Godin focused on designing a non-invasive treatment for the hard-to-treat skin deep infections and on nasal delivery of proteins. She was recruited as a Postdoctoral trainee in the field of Cancer Nanotechnology to the University of Texas Health Sciences Center. Her postdoctoral research focused on injectable multistage nanovectors (MSVs) for cancer treatment and imaging. Her work provided insightful understanding of the interactions of MSVs with immune cells in vivo and in vitro, biocompatibility of MSV, effect of geometry and targeting moieties on MSV biodistribution, and evaluation of MSV systems as near-infra red and MRI imaging agents. In October 2010, Dr. Godin joined the Department of Nanomedicine at the Research Institute.
Research in Dr. Godin's lab, largely funded by federal and foundation grants, focuses on developing physiologically relevant in vitro and in vivo disease models and exploiting physical and biological mechanisms to improve currently available therapeutic options in oncology and obstetrics. Dr. Godin considers herself a translational scientist on the interception of biological and physical sciences, with the ultimate goal of bringing advanced and safe therapies and the techniques to personalize therapies into the clinic to benefit patients.
Dr. Godin has more than 200 scientific publications, received multiple federal and foundation-based grants and participated in multiple national and international grant review panels.
Dr. Godin and her group published numerous peer-reviewed articles, book chapters and reviews in top journals including Nature Nanotechnology, Advanced Functional Materials, Journal of Controlled Release and Cancer Research. She also received national and international awards and other recognitions for her work and is on the editorial board and review board for numerous journals.
Research interests
Dr. Godin's research focuses primarily on the following areas:
-Employing principles of nanomedicine in Ob/Gyn
-Targeting liver metastasis with advanced nanocarriers
-Novel strategies to target tumor microenvironment
-Advanced patient-derived ex vivo disease models for personalized therapies
The main objective of these studies is to provide innovative approaches to treatment and diagnosis of cancer and Ob/Gyn disorders.
Education/Academic qualification
Pharmaceutics, Postdoctoral Fellowship, The Hebrew University of Jerusalem
Pharmaceutical Sciences, PhD, The Hebrew University of Jerusalem
MSc Pharm, The Hebrew University of Jerusalem
Nanomedicine, Postdoctoral Fellowship, University of Texas Health Science Center
External positions
Adjunct Assistant Professor, Obstetrics and Gynecology, University of Texas Health Sciences Center, Houston
Sep 1 2017 → …Adjunct Assistant Professor, Department of Electrical and Computer Engineering, University of Houston
Adjunct Assistant Professor, University of Texas Graduate School of Biomedical Sciences at Houston
Free-text keywords
- Nanomedicine
- Cancer
- Ob/Gyn
- Nano-therapeutics targeting
- Physical sciences in oncology
Research Area Keywords
- Cancer
- Nanomedicine
- Precision Medicine
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
Evaluation of immune responses to CD44-targeted nanovectors for designing a novel anti-tuberculosis host-directed therapy
Godin, B., Jagannath, C. & Leonard, F.
5/1/20 → 4/30/21
Project: Federal Funding Agencies
Study of responses to CD44 targeted nanovectors to design a novel adjunctive anti-tuberculosis host-directed therapy
5/15/19 → 3/28/20
Project: Federal Funding Agencies
Exosome analysis of drug-resistant cancer cells response to nanoparticle therapy
12/1/15 → 11/30/18
Project: Federal Funding Agencies
Ciliary Micropillar Enriched Exosomal microRNA for Cancer Diagnosis by Multiplexed Photonic Crystal Sensor
9/22/15 → 6/21/16
Project: Federal Funding Agencies
Development of Nanovectors to Prevent Placental Passage of a Tocolytic Agent
Univ of Texas Hlth Sci Ctr Houston
8/1/15 → 7/31/17
Project: Federal Funding Agencies
Research Output
Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease
Leonard, F., Srinivasan, S., Liu, X., Collnot, E. M., Ferrari, M., Lehr, C. M. & Godin, B., Jun 1 2020, In : European Journal of Pharmaceutics and Biopharmaceutics. 151, p. 61-72 12 p.Research output: Contribution to journal › Article
Nonlinear response to cancer nanotherapy due to macrophage interactions revealed by mathematical modeling and evaluated in a murine model via CRISPR-modulated macrophage polarization
Leonard, F., Curtis, L. T., Hamed, A. R., Zhang, C., Chau, E., Sieving, D., Godin, B. & Frieboes, H. B., May 1 2020, In : Cancer Immunology, Immunotherapy. 69, 5, p. 731-744 14 p.Research output: Contribution to journal › Article
2
Scopus
citations
Increased soluble crkl in serum of breast cancer patients is associated with advanced disease
Srinivasan, S. & Godin, B., Jul 2019, In : Cancers. 11, 7, 961.Research output: Contribution to journal › Article
1
Scopus
citations
Pre-existing H4K16ac levels in euchromatin drive DNA repair by homologous recombination in S-phase
Horikoshi, N., Sharma, D., Leonard, F., Pandita, R. K., Charaka, V. K., Hambarde, S., Horikoshi, N. T., Gaur Khaitan, P., Chakraborty, S., Cote, J., Godin, B., Hunt, C. R. & Pandita, T. K., Dec 1 2019, In : Communications Biology. 2, 1, 253.Research output: Contribution to journal › Article
3
Scopus
citations
Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma
Borsoi, C., Leonard, F., Lee, Y., Zaid, M., Elganainy, D., Alexander, J. F., Kai, M., Liu, Y. T., Kang, Y., Liu, X., Koay, E. J., Ferrari, M., Godin, B. & Yokoi, K., Sep 10 2017, In : Cancer Letters. 403, p. 296-304 9 p.Research output: Contribution to journal › Article
7
Scopus
citations
Prizes
2016 March of Dimes Award for Best Prematurity Research: Targeted liposomes direct the delivery of indomethacin to the uterus enhancing its tocolytic efficacy to reduce uterine contractions and preterm birth rate
Godin, Biana (Recipient), 2016
Prize: Prize (including medals and awards)
'ATCC Excellence Photograph Award’ for scientific content and image quality
Godin, Biana (Recipient), 2014
Prize: Prize (including medals and awards)
Best PhD thesis in the College of Engineering, Swansea University
Godin, Biana (Recipient), 2015
Prize: Other distinction
FASEB 2014 BioArt Competition: Cell communication in cancer
Godin, Biana (Recipient), 2014
Prize: Other distinction